We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Sangamo Therapeutics Inc | NASDAQ:SGMO | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.0311 | 5.96% | 0.5531 | 0.5531 | 0.5532 | 0.5598 | 0.52 | 0.522 | 894,629 | 20:33:15 |
From May 2019 to May 2024
RICHMOND, Calif., March 1, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), the leader in therapeutic genome editing, announced today that Sandy Macrae, M.B., Ch.B., Ph.D., Sangamo's chief executive officer, will present at the Cowen and Company 37th Annual Health Care Conference on Wednesday, March 8th at 9:20 a.m. Eastern Time. The conference is being held in Boston from March 6-8, 2017.
The presentation will be webcast live and may be accessed via a link on the Sangamo Therapeutics website in the Investor Relations section under Events and Presentation. The presentation will be archived on the Sangamo website for two weeks after the event.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic therapies that transform patients' lives using the company's industry leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. For more information about Sangamo, visit the Company's website at www.sangamo.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/sangamo-therapeutics-announces-presentation-at-the-cowen-and-company-37th-annual-health-care-conference-300416191.html
SOURCE Sangamo Therapeutics, Inc.
Copyright 2017 PR Newswire
1 Year Sangamo Therapeutics Chart |
1 Month Sangamo Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
